

In the Specification:

Paragraph [0057] beginning on page 20, line 11 is amended as follows:

In yet another embodiment, the modified LMWH is used in conjunction with other therapies, such as standard anti-inflammatory therapies, standard ocular therapies, standard dermal therapies, radiotherapy, tumor surgery, and cytotoxic agents or conventional chemotherapy directed against solid tumors and for the control of establishment of ~~metastases~~ metastasis. The administration of the angiogenesis inhibitor is typically conducted during or after chemotherapy at time where the tumor tissue should respond to toxic assault by inducing angiogenesis to recover by the provision of a blood supply and nutrients to the tumor tissue. Additionally, it is preferred to administer such angiogenesis inhibitors after surgery where solid tumors have been removed as a prophylaxis against metastasis. Suitable cytotoxic or chemotherapeutic agents are known in the art and include, but are not limited to, nitrogen mustard, aziridine thiotepa, alkyl sulfonate, nitrosoureas, platinum complexes, ~~no-classic~~ non-classic alkylators, folate analogs, purine analogs, adenosine analogs, pyrimidine analogs, substituted urea, antitumor antibiotics, microtubule agents, and asparaginase.